ATHENS, Greece, via ETELIGIS INC., 03/09/2015 – – HCi Viocare (the "Company") (OTCQB: VICA), is today unveiling the groundbreaking Smart Insole, a connected product that fits into a training shoe, enabling runners to improve their performance and avoid injury.
The first of its kind, the Smart Insole uses a network of tiny sensors to relay comprehensive information about running style back to the wearer via a smart device or mobile for real-time feedback and later analysis.
The sensors in the Smart Insole enable the connected device to display:
– Runners’ foot strike – how and when each part of the foot meets the ground and the pressure and shear forces experienced
– A 3D model of the lower leg gait
– The relative impact on the knee of their different running styles
– The runner’s weight, accurate calories expended, cadence and distance.
Unlike store-based assessments or expensive gait analysis in a clinic, this affordable device allows runners to get direct feedback from their shoes anytime and anywhere, giving them a true picture of their performance out on the road or track.
The information obtained can also be used to select corrective insoles for common problems such as over-pronation or to choose more appropriate footwear. It can even highlight if your shoes are no longer providing the support required or are putting you at increased risk of blisters.
The Company is seeking an established company in the athletics sector for a licensing agreement. Interested parties should contact Heleen Kist on h.kist , who will also be present at the Wearable Technologies show in London on 10 March, 2015.
On behalf of the Board of Directors of HCi Viocare
Chief Executive Officer and President
About HCi Viocare
HCi Viocare has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health & wellbeing areas, for licensing to established industry participants.
The company is listed on the OTC Markets in the USA, has its executive office in Athens, Greece and R&D centre in Glasgow, UK.
For further information about HCi Viocare please visit the Company’s website at http://www.hciviocare.com
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or in finding partners for commercialization of its technologies, including the “Smart Insole”. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Chief Executive Officer and President
SOURCE: HCi Viocare